MedTrace Logo

Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor

NCT06944457 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-25

No results posted yet for this study

Summary

A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor

Conditions

  • Cancer
  • Solid Tumor Cancer
  • Biomarkers

Interventions

DRUG

MPD-1

It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer.

Sponsors & Collaborators

  • Pharosgen Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Sangyoon Kim, MD, PhD · Pharosgen Co.,Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06944457 on ClinicalTrials.gov